Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- MOMO +5.5%,
Other news:
- IPHA +32% (Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma)
- CCCC +16.7% (Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader)
- PRTC +10.9% (Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting)
- AFMD +10.7% (Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients)
- SMCI +9.4% ( Announces Receipt of Extension from Nasdaq Stock Market)
- DADA +9.2% (increases the pool size of its share incentive plan and provides class action update)
- WDAY +9.1% (to join S&P 500)
- PLTR +7.8% (Anduril and Palantir to Accelerate AI Capabilities for National Security)
- CRGX +7.7% (files mixed securities shelf offering)
- SVRE +6.6% (files for 3 mln ADS offering by selling shareholder)
- ACLX +6.5% (Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition)
- APO +6.1% (to join S&P 500)
- BEAM +6% (Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting; Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting)
- OMI +4.9% (awarded a maximum $4.5 bln modification to Defense Logistics Agency contract)
- NOAH +4.8% (Showcases Global Expansion and Investment Product Leadership at 2024 Corporate Open Day)
- KURA +4.4% (Kura Oncology and Kyowa Kirin (KYKOY) Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting)
- DOW +4% (partners with Macquarie Asset Management to launch Diamond Infrastructure Solutions)
- TX +3.8% (affirmed Friday that the Brazilian Court Confirms Ternium's Obligation to Pay Indemnification in connection with its 2012 Acquisition of a Participation in Usiminas; the Decision is subject to further appeals)
- SNDX +3.5% (Presents Positive Revuforj (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting)
- TASK +3.5% (approved a one-year extension of its share repurchase authorization, extending the previously authorized $200 million authorization through December 31, 202)
- THTX +3.5% (announces preliminary tolerability and efficacy data from Phase 1b, dose-ranging trial of sudocetaxel zendusortide in patients with advanced ovarian cancer) M +2.9% (Barington Capital Group calls on Macy's to make changes to its capital allocation plan to improve shareholder value)
- ADCT +2.6% (The Lancet Haematology publication of data from investigator-initiated trial evaluating ZYNLONTA in combination with rituximab to treat relapsed/refractory follicular lymphoma)
- OLMA +2.4% (FDA has cleared its Investigational New Drug application for OP-3136)
- GLPG +2.3% (reports new results from ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with relapsed/refractory non-hodgkin lymphoma)
- ANGO +2.3% (receives FDA clearance for The NanoKnife System for prostate tissue ablation)
- BPMC +2.1% (Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting)
- PLX +1.8% (Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa)
- ZVRA +1.7% (announces organizational changes)
- CRBP +1.6% (Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors)
- AIN +1.2% (increases quarterly dividend by 4% to $0.27/share)
- AES +1% (increases quarterly dividend by 2%)
- IDXX +1% (announces that the Company's Board of Directors authorized an increase in its ongoing share repurchase program, authorizing the repurchase of up to five mln additional shares of the Company's common stock)